Erika Bocanegra: Witnessing 25 Years of Progress in Bleeding Disorders Care
Erika Bocanegra, Director of HTC Business Development and Community Engagement at Luskin Orthopaedic Institute for Children, Lifespan Orthopaedic HTC, shared CHES Foundation, Inc.‘s post on LinkedIn:
“When I first started in the bleeding disorders space 25 years ago, many of the treatment options available today were hard to imagine.
Fast forward to today, and we we’ve witnessed incredible advances, from non-factor therapies and extended half-life products to gene therapy and more personalized approaches to care.
It’s been inspiring to watch the field evolve and, more importantly, to see the positive impact these innovations have had on the lives of patients and families.
Excited to see what the future holds!”
CHES Foundation, Inc. shared a post on LinkedIn:
“HYMPAVZI is now approved for people with hemophilia A or B ages 12+ with inhibitors, as well as children ages 6–11 with or without inhibitors.
This milestone also makes HYMPAVZI the first subcutaneous non-factor therapy available for children with hemophilia B ages 6–11.”
Stay updated with Hemostasis Today.
-
Aug 23, 2026, 16:35Thomas Dayspring: The Overlooked Pathway in Cholesterol Homeostasis
-
Aug 23, 2026, 16:28Evan Mapelu: The People Who Make Cancer Care Meaningful
-
Aug 23, 2026, 16:09Felice Gragnano: New Publication on Aspirin Discontinuation After PCI for Acute Coronary Syndromes
-
Aug 23, 2026, 16:06Mostafa Faisal: Donor Type and Long-Term Quality of Life After HCT for Severe Aplastic Anemia
-
Aug 23, 2026, 10:10Sthanu Subramanian: Empagliflozin and a Rise in Hematocrit
-
Aug 23, 2026, 16:03Balaji Balagani: Major Causes of Sudden Cardiac Death in Children
-
Aug 23, 2026, 16:02Bartosz Hudzik: What’s Hot at ESC Congress 2026
-
Aug 23, 2026, 16:01Jim Hoffman: NETs in STEMI and Their Association With PCI and Antithrombotic Treatments
-
Aug 23, 2026, 16:01Luis Oliverio Ambriz Garcia: Key Insights Into Myeloproliferative Neoplasms From the 2026 NEJM Review